FXR–FGF15/19 STAT5 Signaling Coordinates Hepatocyte Protection and Immune Resolution in LCA-Induced Cholestatic Liver Injury

Background: Cholangiopathies, such as primary sclerosing cholangitis (PSC) involve bile acid toxicity, epithelial injury, and innate immune activation. While FXR regulates bile acid homeostasis, it remains unknown whether different FXR agonists elicit distinct protective responses. To determine whether early FXR activation can prevent the development of lithocholic acid (LCA)-induced cholestatic injury, we administered FXR agonists during LCA exposure and evaluated their effects on hepatocyte, immune, and endocrine responses. Methods: Adult male C57BL/6 mice were fed a 1%; LCA diet for 2 days and treated by intravenous infusion with FXR agonists GW4064 (30 mg/kg/day) or obeticholic acid (OCA; 20 mg/kg/day) for 4 days, initiated 2 days before LCA exposure. Liver injury was assessed by serum biochemistry, histology, immunostaining, intrahepatic mononuclear cell profiling, ChIP assay, and bulk liver RNA sequencing. Huh7 and T84 cells were used for co-culture. Results: LCA induced marked cholestatic injury with elevated liver enzymes, bile duct injury, macrophage and neutrophil infiltration, and activation of inflammatory, oxidative stress, apoptotic, and MYC-dependent transcriptional programs. FXR agonists prevented biochemical and histologic injury, restored hepatocyte bile acid transport and feedback regulation, reduced oxidative stress and apoptosis, and attenuated coordinated macrophage–neutrophil activation. Transcriptomic analyses revealed agonist-dependent effects, with GW4064 and OCA suppressing LCA-induced injury pathways. FXR activation induced ileal FXR targets and Fgf15, reduced intestinal macrophage infiltration, and activated hepatic STAT5 signaling. Direct FGF19 treatment of Huh7 cells recapitulated hepatocyte protective effects and STAT5 activation. Conclusions: FXR agonist treatment mitigates LCA-induced cholestatic liver injury by restoring hepatocyte bile acid homeostasis, suppressing innate immune inflammation, and engaging an ileal FXR–FGF15/19–hepatic STAT5 survival axis, with distinct agonist-dependent transcriptional outcomes.

Authors

Institutions

Publication Details

Journal
American Journal of Physiology-Gastrointestinal and Liver Physiology
Published
2026-11-13
DOI
https://doi.org/10.1152/ajpgi.90008.2026
Primary Topic
Drug Transport and Resistance Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FXR–FGF15/19 STAT5 Signaling Coordinates Hepatocyte Protection and Immune Resolution in LCA-Induced Cholestatic Liver Injury

Swati Ghosh, Ronald J. Sokol, Himangi Srivastava, David J. Orlicky et al.
American Journal of Physiology-Gastrointestinal and Liver Physiology
Drug Transport and Resistance Mechanisms
article

FXR–FGF15/19 STAT5 Signaling Coordinates Hepatocyte Protection and Immune Resolution in LCA-Induced Cholestatic Liver Injury

Swati Ghosh, Ronald J. Sokol, Himangi Srivastava, David J. Orlicky, Michael W. Devereaux
article en

Abstract

Background: Cholangiopathies, such as primary sclerosing cholangitis (PSC) involve bile acid toxicity, epithelial injury, and innate immune activation. While FXR regulates bile acid homeostasis, it remains unknown whether different FXR agonists elicit distinct protective responses. To determine whether early FXR activation can prevent the development of lithocholic acid (LCA)-induced cholestatic injury, we administered FXR agonists during LCA exposure and evaluated their effects on hepatocyte, immune, and endocrine responses. Methods: Adult male C57BL/6 mice were fed a 1%; LCA diet for 2 days and treated by intravenous infusion with FXR agonists GW4064 (30 mg/kg/day) or obeticholic acid (OCA; 20 mg/kg/day) for 4 days, initiated 2 days before LCA exposure. Liver injury was assessed by serum biochemistry, histology, immunostaining, intrahepatic mononuclear cell profiling, ChIP assay, and bulk liver RNA sequencing. Huh7 and T84 cells were used for co-culture. Results: LCA induced marked cholestatic injury with elevated liver enzymes, bile duct injury, macrophage and neutrophil infiltration, and activation of inflammatory, oxidative stress, apoptotic, and MYC-dependent transcriptional programs. FXR agonists prevented biochemical and histologic injury, restored hepatocyte bile acid transport and feedback regulation, reduced oxidative stress and apoptosis, and attenuated coordinated macrophage–neutrophil activation. Transcriptomic analyses revealed agonist-dependent effects, with GW4064 and OCA suppressing LCA-induced injury pathways. FXR activation induced ileal FXR targets and Fgf15, reduced intestinal macrophage infiltration, and activated hepatic STAT5 signaling. Direct FGF19 treatment of Huh7 cells recapitulated hepatocyte protective effects and STAT5 activation. Conclusions: FXR agonist treatment mitigates LCA-induced cholestatic liver injury by restoring hepatocyte bile acid homeostasis, suppressing innate immune inflammation, and engaging an ileal FXR–FGF15/19–hepatic STAT5 survival axis, with distinct agonist-dependent transcriptional outcomes.

American Journal of Physiology-Gastrointestinal and Liver Physiology
Fred Hutch Cancer Center (US), University of Colorado Anschutz Medical Campus (US)
Drug Transport and Resistance Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon